Literature DB >> 20713558

Migraine symptomatology and major depressive disorder.

Lannie Ligthart1, Brenda W J H Penninx, Dale R Nyholt, Marijn A Distel, Eco J C de Geus, Gonneke Willemsen, Johannes H Smit, Dorret I Boomsma.   

Abstract

INTRODUCTION AND
OBJECTIVE: Migraine and major depressive disorder (MDD) frequently co-occur, but it is unclear whether depression is associated with a specific subtype of migraine. The objective of this study was to investigate whether migraine is qualitatively different in MDD patients (N = 1816) and non-depressed controls (N = 3428).
METHODS: Migraine symptom data were analyzed using multi-group Latent Class Analysis, and a qualitative comparison was made between the symptom profiles of MDD patients and controls, while allowing for differences in migraine prevalence and severity between groups.
RESULTS: In both groups, three migrainous headache classes were identified, which differed primarily in terms of severity. Both mild and severe migrainous headaches were two to three times more prevalent in MDD patients. Migraine symptom profiles showed only minor qualitative differences in the MDD and non-MDD groups: in the severe migrainous headache class, significant differences were observed only in the prevalence of aggravation by physical activity (83% and 91% for the non-MDD and MDD groups, respectively) and aura (42% vs. 53%, respectively).
CONCLUSION: The similar overall symptom profiles observed in the MDD and non-MDD subjects suggest that a similar disease process may underlie migraine in both groups.

Entities:  

Mesh:

Year:  2010        PMID: 20713558     DOI: 10.1177/0333102410363492

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

1.  Multimodal behavioral treatment of migraine: an Internet-administered, randomized, controlled trial.

Authors:  Kerstin Hedborg; Carin Muhr
Journal:  Ups J Med Sci       Date:  2011-04-20       Impact factor: 2.384

2.  The Impacts of Migraine among Outpatients with Major Depressive Disorder at a Two-Year Follow-Up.

Authors:  Ching-I Hung; Chia-Yih Liu; Ching-Hui Yang; Shuu-Jiun Wang
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

3.  Decreased Openness to Experience Is Associated with Migraine-Type Headaches in Subjects with Lifetime Depression.

Authors:  Mate Magyar; Xenia Gonda; Dorottya Pap; Andrea Edes; Attila Galambos; Daniel Baksa; Natalia Kocsel; Edina Szabo; Gyorgy Bagdy; Rebecca Elliott; Gyongyi Kokonyei; Gabriella Juhasz
Journal:  Front Neurol       Date:  2017-06-22       Impact factor: 4.003

4.  Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications.

Authors:  Thomas Dresler; Salvatore Caratozzolo; Kaat Guldolf; Jana-Isabel Huhn; Carmela Loiacono; Triinu Niiberg-Pikksööt; Marta Puma; Giorgia Sforza; Anna Tobia; Raffaele Ornello; Gianluca Serafini
Journal:  J Headache Pain       Date:  2019-05-09       Impact factor: 7.277

5.  Classifying migraine subtypes and their characteristics by latent class analysis using data of a nation-wide population-based study.

Authors:  Wonwoo Lee; In Kyung Min; Kwang Ik Yang; Daeyoung Kim; Chang-Ho Yun; Min Kyung Chu
Journal:  Sci Rep       Date:  2021-11-03       Impact factor: 4.379

6.  Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders.

Authors:  Lannie Ligthart; Jouke-Jan Hottenga; Cathryn M Lewis; Anne E Farmer; Ian W Craig; Gerome Breen; Gonneke Willemsen; Jacqueline M Vink; Christel M Middeldorp; Enda M Byrne; Andrew C Heath; Pamela A F Madden; Michele L Pergadia; Grant W Montgomery; Nicholas G Martin; Brenda W J H Penninx; Peter McGuffin; Dorret I Boomsma; Dale R Nyholt
Journal:  Hum Genet       Date:  2013-10-01       Impact factor: 4.132

7.  Migraine predicts physical and pain symptoms among psychiatric outpatients.

Authors:  Ching-I Hung; Chia-Yih Liu; Shuu-Jiun Wang
Journal:  J Headache Pain       Date:  2013-02-27       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.